|

Overview
| Day 1 | Day
2 | Day 3 | Download
Brochure | Breakout
Discussions
|
Recommended Short Courses*
|
(SC6) Best Practices in Translational Medicine, Drug Discovery, and Informatics (Click
on the title to view the full description)
|
|
TUESDAY, FEBRUARY 24
This course provides you with an inside look at several of the outstanding Best
Practices presented as a part of the 2008 Bio-IT World Best Practices
competition. Speakers will present their best practices, give updates to the
program and discuss pushing innovation, increasing ROI, and implementing
strategies that are the best in the industry. The forum will be invaluable for
building the innovative partnerships and strategies that will keep pushing the
industry forward.
Agenda
2:00 Chairperson’s Introduction
Kevin Davies, Ph.D., Chief Editor, Bio-IT World
2:15 Genstruct & Sirtris Pharmaceuticals: Causal Network Modeling: A powerful
approach to modeling complex biological systems
Renee Kenney, Ph.D; Director, Scientific Research; Genstruct
Genstruct has developed a unique causal network modeling (CNM) platform for
systems biology that has been applied successfully to biomarker discovery,
mechanism of action (MOA) definition and drug safety assessment. Sirtris
Pharmaceuticals and Genstruct have collaborated to characterize the molecular
MOA of a revolutionary set of bioactive, Sirt1 activating small molecules.
2:45 Merck & Moffitt Cancer Center: The Biomarker Information Pipeline
Brenda Yanak, Lead, Translational Medicine Informatics and IT, Merck Research Laboratories, West Point, PA
The Biomarker Information Pipeline is a collaboration between the H. Lee Moffitt
Cancer Center & Research Institute (MCC) and Merck & Company. The Pipeline
automates flow and integration of: longitudinal patient care data associated
with bio-specimen and research data from MCC with gene expression and other
profiling data derived from analysis of tumor biosamples.
3:15 Refreshment Break
3:30 Johnson & Johnson: Advanced Biology and Chemistry Discovery (ABCD)
Victor Lobanov, Ph.D., Director, Research & Early Development (RED) IT; Johnson
& Johnson
Advanced Biology and Chemistry Discovery (ABCD) is a modern drug discovery
informatics platform for Johnson & Johnson Pharmaceutical Research & Development
(J&JPRD). It is an attempt to bridge multiple continents, data systems and
cultures using modern information technology, and provide scientists with tools
that allow them to make better decisions.
4:00 National Cancer Institute: cancer Biomedical Informatics Grid (caBIG)
Dr. George Komatsoulis, Deputy Director, acting COO and Chief, Informatics
Operations Branch, Center for Biomedical Informatics and Information Technology,
National Cancer Institute
Recognizing that the ability to connect people, organizations, and data through
IT is critical to realizing the potential of molecular medicine, NCI created the
cancer Biomedical Informatics Grid (caBIG). This open-source network seeks to
speed research discoveries and improve patient outcomes by overcoming the silos
and data disconnects that slow cancer research.
4:30 Genentech & Dolcera: Innovation Dashboard
Fabrice Beretta, Principal, Process Research and Development; Business
Excellence, Strategy and Training, Genentech
Samir Raiyani, CEO, Dolcera
Genentech is using the Dolcera Innovation Dashboard for two new innovation
initiatives related to product research and development. This dashboard helps
Genentech identify technology trends, key competitors, opportunities for new
product development, experts, startups and universities active in the areas of
interest, and execution strategy for new ideas.
5:00 Session Wrap-up
|
*Separate Registration Required |
Pre-Conference Short Course
Tuesday, February 24
(SC6) Best Practices in Translational Medicine,
Drug Discovery, and Informatics
Session Topics Include
-
Integrated R&D – Driving Productivity, Innovation & Managing Resources & Costs
-
Translational Research Informatics
-
Data, Information and Knowledge Management
-
Integrating Genomic Data
-
Data Integration and Management for Early and Late Chemistry
Breakout Discussion Groups
Panel Discussions
Integrated R&D – How Far Have We Come?
Bridging the Divide
DISTINGUISHED FACULTY:
Toby Bloom, The Broad Institute
Ken Buetow, National Cancer Institute
Joseph A. Cerro, The Schooner Group, LLC
Jeffrey D. Christoffersen, Eli Lilly & Co.
Nikolai Daraselia, Ariadne
Jakob DeVlieg, Schering-Plough
David Ewing Duncan, NPR Talk’s “Biotech Nation” and Best Selling Author “Masterminds”
Juergen Hammer, Hoffmann-La Roche Inc.
Reece Hart, Genentech Inc.
David M. Hodgson, Roche
Aubree Hoover, Rosetta Biosoftware
Jason M. Johnson, Merck & Co., Inc.
Anastasia M. Khoury Christianson, AstraZeneca R&D Wilmington
Michael, Lajiness, Eli Lilly & Company
Martin D. Leach, Merck & Co. Inc.
Jeanette Papp, University of California, Los Angeles
John Russell, Bio-IT World
Stephan Schürer, University of Miami
David M. Sedlock, Millennium Pharmaceuticals
Ajay Shah, Elan Pharmaceuticals, Inc.
Sandor Szalma, Centocor R&D Inc.
Jay M. Tenenbaum, CollabRx, Inc.
Chris Waller, Pfizer, Inc.
Susan Ward, Biotechnology & Pharma
James A. Wells, University of California, San Francisco
Hans-Martin Will, Rosetta Biosoftware
Overview
| Day 1 | Day
2 | Day 3 | Download
Brochure | Breakout
Discussions
For questions or suggestions about the meeting, please contact:
Edel O'Regan
Cambridge Healthtech Institute
250 First Avenue, Suite #300
Needham, MA 02494
Tel: 781-972-5423
Fax: 781-972-5425
email: eoregan@healthtech.com
For sales
information, contact:
Carol Dinerstein
Tel: 781-972-5471
email: Dinerstein@healthtech.com
OR
Jon Stroup
Tel: 781-972-5483
email: jstroup@healthtech.com
|
2009 Final
Brochure Download
|